Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. (Q35838373)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257626%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

review article

1 reference

title

Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257626%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257626%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Paul Abrams

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257626%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

publication date

1 January 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257626%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257626%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257626%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257626%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

1643-1656

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257626%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00003495-200464150-00003

30 December 2019

exact match

0 references

cites work

Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group

1 reference

12 December 2020

Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups

1 reference

12 December 2020

Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder

1 reference

12 December 2020

Behavioral intervention for community-dwelling individuals with urinary incontinence

1 reference

12 December 2020

Biofeedback in overactive bladder

1 reference

12 December 2020

Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers

1 reference

12 December 2020

Clinical efficacy of tolterodine with or without a simplified pelvic floor exercise regimen

1 reference

12 December 2020

Prevalence and burden of overactive bladder in the United States

1 reference

12 December 2020

Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group

1 reference

12 December 2020

Describing bladder storage function: overactive bladder syndrome and detrusor overactivity

1 reference

12 December 2020

Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study

1 reference

12 December 2020

Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

1 reference

12 December 2020

A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence.

1 reference

12 December 2020

Measurement characteristics of a voiding diary for use by men and women with overactive bladder

1 reference

12 December 2020

The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

1 reference

12 December 2020

ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence

1 reference

12 December 2020

1 reference

12 December 2020

The role of neuromodulation in the management of urinary urge incontinence

1 reference

12 December 2020

A neurologic basis for the overactive bladder

1 reference

12 December 2020

Costs of urinary incontinence and overactive bladder in the United States: a comparative study.

1 reference

12 December 2020

Muscarinic receptor subtypes and management of the overactive bladder

1 reference

12 December 2020

Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results

1 reference

12 December 2020

Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

1 reference

12 December 2020

Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder

1 reference

12 December 2020

Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group

1 reference

12 December 2020

European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity

1 reference

12 December 2020

Scoring the short form ICSmaleSF questionnaire. International Continence Society

1 reference

12 December 2020

Frequency-volume chart: the minimum number of days required to obtain reliable results

1 reference

12 December 2020

Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group.

1 reference

12 December 2020

Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder.

1 reference

12 December 2020

1 reference

12 December 2020

Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis

1 reference

12 December 2020

Trospium chloride: an effective option for medical treatment of bladder overactivity.

1 reference

12 December 2020

Effectiveness of intravesical resiniferatoxin in treating detrusor hyper‐reflexia and external sphincter dyssynergia in patients with chronic spinal cord lesions

1 reference

12 December 2020

Muscarinic receptors: What we know

1 reference

12 December 2020

Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial.

1 reference

12 December 2020

Behavioral therapy for overactive bladder

1 reference

12 December 2020

A case-control study to examine any association between idiopathic detrusor instability and gastrointestinal tract disorder, and between irritable bowel syndrome and urinary tract disorder.

1 reference

12 December 2020

Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine

1 reference

12 December 2020

Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic).

1 reference

12 December 2020

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

1 reference

12 December 2020

Desensitization of bladder sensory fibers by intravesical resiniferatoxin, a capsaicin analog: long-term results for the treatment of detrusor hyperreflexia.

1 reference

12 December 2020

Economic considerations and outcome measurement in urge incontinence.

1 reference

12 December 2020

Antimuscarinics for treatment of overactive bladder

1 reference

12 December 2020

Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence

1 reference

12 December 2020

Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET).

1 reference

12 December 2020

Caffeine: does it affect your bladder?

1 reference

12 December 2020

Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.

1 reference

12 December 2020

A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance.

1 reference

12 December 2020

Cholinergic modulation of memory in the basolateral amygdala involves activation of both m1 and m2 receptors

1 reference

12 December 2020

Effect of Behavioral Training With or Without Pelvic Floor Electrical Stimulation on Stress Incontinence in Women

1 reference

12 December 2020

Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability

1 reference

12 December 2020

Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder

1 reference

12 December 2020

Pharmacological Effects of Darifenacin on Human Isolated Urinary Bladder

1 reference

12 December 2020

Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review

1 reference

12 December 2020

Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects

1 reference

12 December 2020

Surgical management of overactive bladder

1 reference

12 December 2020

Modulation of autonomous contractile activity in the isolated whole bladder of the guinea pig.

1 reference

12 December 2020

Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial

1 reference

12 December 2020

A myogenic basis for the overactive bladder

1 reference

12 December 2020

Trospium chloride in patients with detrusor overactivity: meta-analysis of placebo-controlled, randomized, double-blind, multi-center clinical trials on the efficacy and safety of 20 mg trospium chloride twice daily

1 reference

12 December 2020

Treatment of overactive bladder with modified intravesical oxybutynin chloride

1 reference

12 December 2020

Influence of behavior modification on overactive bladder

1 reference

12 December 2020